{"id":6272,"date":"2019-10-28T12:16:59","date_gmt":"2019-10-28T06:46:59","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6272"},"modified":"2025-05-08T12:06:46","modified_gmt":"2025-05-08T06:36:46","slug":"refractory-metastatic-melanoma-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/refractory-metastatic-melanoma-market","title":{"rendered":"\ufeffRefractory Metastatic Melanoma Market"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fdcc4c862bc\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fdcc4c862bc\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/refractory-metastatic-melanoma-market\/#Refractory_Metastatic_Melanoma_Therapeutics_landscape\" >Refractory Metastatic Melanoma\nTherapeutics landscape<\/a><ul class='ez-toc-list-level-5' ><li class='ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/refractory-metastatic-melanoma-market\/#Refractory_Metastatic_Melanoma_Approved_Therapies\" >Refractory Metastatic Melanoma Approved Therapies<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/refractory-metastatic-melanoma-market\/#Companies_fuelling_the_Refractory_Metastatic_Melanoma_Market\" >Companies fuelling the Refractory\nMetastatic Melanoma Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/refractory-metastatic-melanoma-market\/#Refractory_Metastatic_Melanoma_Pipeline_products\" >Refractory Metastatic Melanoma\nPipeline products<\/a><\/li><\/ul><\/nav><\/div>\n\n<p class=\"has-drop-cap\">The cases of Melanoma have been on a hike for the past thirty years making it the fifth most common cancer among people. By the end of the year 2019, an estimated number of 57,220 men and 39,260 women in the United States would have been diagnosed with invasive melanoma, as per Cancer.net.<\/p>\n\n\n\n<p>Melanoma is the rarest form of skin cancer which initiates its journey in melanocytes. It can develop anywhere in the body including head, neck, underneath of fingernails, or even the soles of feet and palms of the hands. <\/p>\n\n\n\n<p>As per a study by Skin Cancer Foundation, only 20-30% of the melanomas arise from moles, and the remaining 70-80% arise from normal-looking skin. <\/p>\n\n\n\n<p>The Melanoma diagnosis at the early stage is important as it has higher chances to be rectified through surgery. Cancer, if not diagnosed early, has most chances to takes malignant form. It can spread deeply into the skin, into the lymph nodes and blood vessels and ultimately leading to death. <\/p>\n\n\n\n<p style=\"background-color:#848181\" class=\"has-text-color has-background has-very-light-gray-color\"> According to Cancer.net, an estimated number of 7,230 deaths from melanoma will occur by the end of this year. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Refractory_Metastatic_Melanoma_Therapeutics_landscape\"><\/span><strong>Refractory Metastatic Melanoma\nTherapeutics landscape<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>The Refractory Metastatic Melanoma treatment aims to prolong survival, eliminate cancer, shrink or halt the growth of known metastases. Moreover, the Refractory Metastatic Melanoma therapies provide comfort and stop the growth of the tumour at-risk areas. <\/p>\n\n\n\n<p>The Refractory Metastatic Melanoma treatment\nlandscape comprises of immunotherapy, targeted therapy, intralesional therapy,\nchemotherapy, and radiation therapy. However, surgery is also considered as an\noption for certain cases.<\/p>\n\n\n\n<p>Immunotherapy helps boost the body\u2019s natural defences to fight cancer. Recent years have seen major advances in stage IV of the Refractory Metastatic Melanoma treatment with immunotherapy. Three immunotherapy-based drugs such as Nivolumab, a product of Bristol-Myers Squibb, Pembrolizumab by Merck &amp; Co, and Ipilimumab, again a candidate of Bristol-Myers Squibb hold the approved Refractory <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/malignant-melanoma-epidemiology-forecast\">Metastatic Melanoma<\/a> <\/strong>drug tags. <\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Refractory_Metastatic_Melanoma_Approved_Therapies\"><\/span><strong>Refractory Metastatic Melanoma Approved Therapies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<p>Nivolumab (Opdivo) and Pembrolizumab\nare now considered as the first treatment option for Refractory Metastatic\nMelanoma patient pool. Nivolumab and Pembrolizumab, both the Anti-PD-1\nantibodies, are efficiently shrink melanoma in around 25-45% of the patients. <\/p>\n\n\n\n<p>Targeted Refractory Metastatic Melanoma therapy is a treatment that targets cancer-promoting specific genes, proteins, or the tissue environment.&nbsp; Undoubtedly, targeted Melanoma therapy improves patient survival as it blocks the growth and proliferation of cancer cells while limiting damage to healthy cells. Three Refractory Metastatic Melanoma targeted therapies that have received the FDA approval so far are Dabrafenib (Novartis), Vemurafenib (Roche), and Trametinib (Novartis).<\/p>\n\n\n\n<p>Dabrafenib and Vemurafenib occupy major chunk of the Refractory Metastatic Melanoma therapy market because of their property to inhibit <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/braf-mutant-metastatic-melanoma-market\">BRAF<\/a><\/strong>. Around 40\u2013 50% of patients have tumours that harbour BRAF V600 mutations, which leads to a rapid progression of the melanoma. In the case of the BRAF mutations, Dabrafenib and Vemurafenib become major relief providing Refractory Metastatic Melanoma drugs. <\/p>\n\n\n\n<p>On the other hand, Trametinib is a\nMEK-inhibitor. <\/p>\n\n\n\n<p>Larotrectinib (Loxo Oncology Inc\/Bayer) is a type of targeted therapy, which is not specific to a certain type of cancer but focuses on a specific genetic change called an NTRK fusion. This type of genetic change is found in a range of cancers, including melanoma.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Companies_fuelling_the_Refractory_Metastatic_Melanoma_Market\"><\/span><strong>Companies fuelling the Refractory\nMetastatic Melanoma Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Certain key pharma and biotech companies that are working to develop new Refractory Metastatic Melanoma therapies are Idera Pharmaceuticals and Iovance Biotherapeutics. The therapies are in different phases of development. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Refractory_Metastatic_Melanoma_Pipeline_products\"><\/span><strong>Refractory Metastatic Melanoma\nPipeline products <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Idera Pharmaceuticals is developing<strong>\nIMO-2125<\/strong>, a toll-like receptor (TLR) 9 agonist. Designated as Orphan Drug and\nFast-track by the US FDA, the drug is under Phase- III clinical trials. <\/p>\n\n\n\n<p>Furthermore, Iovance Biotherapeutics is running Phase III trials for LN-144 which is a tumor-Infiltrating Lymphocyte (TIL) therapy for Refractory Metastatic Melanoma treatment. <\/p>\n\n\n\n<p>Derived from a patient\u2019s own immune\ncells called T lymphocytes, the drug has already received a Fast Track\ndesignation from the US FDA for Stage IIIc or IV Refractory Metastatic Melanoma\ntreatment. Iovance aims to depict the safety and efficacy of its candidate\nthrough the trials. <\/p>\n\n\n\n<p>The results of the trials of the drugs for Refractory Metastatic Melanoma and the launch of the respective pipeline products points towards positive growth of the Refractory Metastatic Melanoma market in the 7MM in the coming years, forecast DelveInsight\u2019s analysts. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>The cases of Melanoma have been on a hike for the past thirty years making it the fifth most common cancer among people. By the end of the year 2019, an estimated number of 57,220 men and 39,260 women in the United States would have been diagnosed with invasive melanoma, as per Cancer.net. Melanoma is [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6273,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[6686,6687,6688],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-6272","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-refractory-metastatic-melanoma-market","tag-refractory-metastatic-melanoma-therapy-market","tag-refractory-metastatic-melanoma-treatment-market","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\ufeffRefractory Metastatic Melanoma Market - DelveInsight<\/title>\n<meta name=\"description\" content=\"Launch of the Refractory Metastatic Melanoma pipeline products points towards positive growth of the Refractory Metastatic Melanoma market in the 7MM.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/refractory-metastatic-melanoma-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeffRefractory Metastatic Melanoma Market - DelveInsight\" \/>\n<meta property=\"og:description\" content=\"Launch of the Refractory Metastatic Melanoma pipeline products points towards positive growth of the Refractory Metastatic Melanoma market in the 7MM.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/refractory-metastatic-melanoma-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-28T06:46:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T06:36:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022450\/image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\ufeffRefractory Metastatic Melanoma Market - DelveInsight","description":"Launch of the Refractory Metastatic Melanoma pipeline products points towards positive growth of the Refractory Metastatic Melanoma market in the 7MM.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/refractory-metastatic-melanoma-market","og_locale":"en_US","og_type":"article","og_title":"\ufeffRefractory Metastatic Melanoma Market - DelveInsight","og_description":"Launch of the Refractory Metastatic Melanoma pipeline products points towards positive growth of the Refractory Metastatic Melanoma market in the 7MM.","og_url":"https:\/\/www.delveinsight.com\/blog\/refractory-metastatic-melanoma-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-10-28T06:46:59+00:00","article_modified_time":"2025-05-08T06:36:46+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022450\/image.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/refractory-metastatic-melanoma-market","url":"https:\/\/www.delveinsight.com\/blog\/refractory-metastatic-melanoma-market","name":"\ufeffRefractory Metastatic Melanoma Market - DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/refractory-metastatic-melanoma-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/refractory-metastatic-melanoma-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022450\/image.jpg","datePublished":"2019-10-28T06:46:59+00:00","dateModified":"2025-05-08T06:36:46+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Launch of the Refractory Metastatic Melanoma pipeline products points towards positive growth of the Refractory Metastatic Melanoma market in the 7MM.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/refractory-metastatic-melanoma-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/refractory-metastatic-melanoma-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022450\/image.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022450\/image.jpg","width":772,"height":482,"caption":"Refractory Metastatic Melanoma Market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022450\/image-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Refractory Metastatic Melanoma Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Refractory Metastatic Melanoma Therapy Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Refractory Metastatic Melanoma treatment Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Refractory Metastatic Melanoma Market<\/span>","<span class=\"advgb-post-tax-term\">Refractory Metastatic Melanoma Therapy Market<\/span>","<span class=\"advgb-post-tax-term\">Refractory Metastatic Melanoma treatment Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Oct 28, 2019","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on Oct 28, 2019 12:16 pm","modified":"Updated on May 8, 2025 12:06 pm"},"featured_img_caption":"Refractory Metastatic Melanoma Market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6272"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6272\/revisions"}],"predecessor-version":[{"id":31910,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6272\/revisions\/31910"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6273"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6272"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6272"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6272"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}